R&D News | pharmaphorum

News

Vertex buys Crinetics for $10bn in endocrinology drive

Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.

News

Roche looks to Astex in $515m breast cancer deal

Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.

News

Novartis snaps up UK ADC developer Myricx Bio

Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.

News

Scribe Therapeutics joins the IPO queue

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

News

Trial of Bundibugyo Ebola drugs starts in DRC

Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.

News

Respiratory biotech Celea raises $180m, and other financings

This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum.

Vertex buys Crinetics for $10bn in endocrinology drive

Roche looks to Astex in $515m breast cancer deal

Novartis snaps up UK ADC developer Myricx Bio

Scribe Therapeutics joins the IPO queue

Trial of Bundibugyo Ebola drugs starts in DRC

Respiratory biotech Celea raises $180m, and other financings

US puts $125m into personalised RNA therapy production

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks